135 related articles for article (PubMed ID: 8737633)
21. Profound mishandling of protein glycation degradation products in uremia and dialysis.
Agalou S; Ahmed N; Babaei-Jadidi R; Dawnay A; Thornalley PJ
J Am Soc Nephrol; 2005 May; 16(5):1471-85. PubMed ID: 15800128
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological preconditioning of ischaemia.
Laghi Pasini F; Capecchi PL; Acciavatti A; Petri S; de Lalla A; Cati G; Colafati M; Di Perri T
Clin Hemorheol Microcirc; 1997; 17(1):73-84. PubMed ID: 9181761
[TBL] [Abstract][Full Text] [Related]
23. [Improved kidney function with intravenous prostaglandin E1 in patients with terminal heart failure].
Wutte M; Hülsmann M; Berger R; Rödler S; Frey B; Stanek B; Pacher R
Wien Klin Wochenschr; 1998 Jul; 110(13-14):473-8. PubMed ID: 9746960
[TBL] [Abstract][Full Text] [Related]
24. Accumulation of vitamin E metabolites in the blood of renal failure patients.
Galli F; Floridi AG; Floridi A; Buoncristiani U
Clin Nutr; 2004 Apr; 23(2):205-12. PubMed ID: 15030960
[TBL] [Abstract][Full Text] [Related]
25. Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis.
Teigen MM; Duffull S; Dang L; Johnson DW
J Clin Pharmacol; 2006 Nov; 46(11):1259-67. PubMed ID: 17050791
[TBL] [Abstract][Full Text] [Related]
26. Urea kinetics and dialysis treatment time predict vancomycin elimination during high-flux hemodialysis.
Schaedeli F; Uehlinger DE
Clin Pharmacol Ther; 1998 Jan; 63(1):26-38. PubMed ID: 9465839
[TBL] [Abstract][Full Text] [Related]
27. A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension.
Petersen LJ; Petersen JR; Talleruphuus U; Møller ML; Ladefoged SD; Mehlsen J; Jensen HA
Clin Nephrol; 2001 May; 55(5):375-83. PubMed ID: 11393383
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis.
Eriksson T; Höglund P; Turesson I; Waage A; Don BR; Vu J; Scheffler M; Kaysen GA
J Pharm Pharmacol; 2003 Dec; 55(12):1701-6. PubMed ID: 14738599
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients.
Vanholder R; Camez A; Veys N; Van Loo A; Dhondt AM; Ringoir S
Thromb Haemost; 1997 Apr; 77(4):650-5. PubMed ID: 9134637
[TBL] [Abstract][Full Text] [Related]
31. The effect of increasing dialysis dose in overweight hemodialysis patients on quality of life: a 6-week randomized crossover trial.
Wang W; Tonelli M; Hemmelgarn B; Gao S; Johnson JA; Taub K; Manns B;
Am J Kidney Dis; 2008 May; 51(5):796-803. PubMed ID: 18436090
[TBL] [Abstract][Full Text] [Related]
32. [Pioneer experience with buflomedil in the form of retrograde venous pulse therapy for treatment of ischemia and severe extremity infections].
Cavini-Ferreira PC
Wien Med Wochenschr; 1993; 143(7-8):193-4. PubMed ID: 8379175
[TBL] [Abstract][Full Text] [Related]
33. Increased binding of beta-2-microglobulin to blood cells in dialysis patients treated with high-flux dialyzers compared with low-flux membranes contributed to reduced beta-2-microglobulin concentrations. Results of a cross-over study.
Traut M; Haufe CC; Eismann U; Deppisch RM; Stein G; Wolf G
Blood Purif; 2007; 25(5-6):432-40. PubMed ID: 17957097
[TBL] [Abstract][Full Text] [Related]
34. Improving the efficiency of short-term single-needle hemodialysis.
Rostoker G; Griuncelli M; Loridon C; Bourlet T; Welsch K; Benmaadi A
Ren Fail; 2009; 31(4):261-6. PubMed ID: 19462273
[TBL] [Abstract][Full Text] [Related]
35. [Nuclear medicine studies of tissue concentration and hemodynamic effects of retrograde intravenous pressure infusions].
Partsch H; Jochmann W; Mostbeck A; Hirschl M
Wien Med Wochenschr; 1993; 143(7-8):172-6. PubMed ID: 8397459
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of two buflomedil tablet formulations in patients with atherosclerotic disease.
Molinaro M; Regazzi MB; Raffaghello S; Buggia I; Iacona I; Graziani P; Specchia G; Melzi D'eril G
J Clin Pharm Ther; 1994 Apr; 19(2):111-5. PubMed ID: 8071390
[TBL] [Abstract][Full Text] [Related]
37. [Factors which influence phosphorus removal in hemodialysis].
Gallar P; Ortiz M; Ortega O; Rodríguez I; Seijas V; Carreño A; Oliet A; Vigil A
Nefrologia; 2007; 27(1):46-52. PubMed ID: 17402879
[TBL] [Abstract][Full Text] [Related]
38. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
39. Tissular oxygenation and venoarteriolar reflex disturbances in diabetes mellitus: vasoregulator effect of Buflomedil.
Le Devehat C; Khodabandehlou T; Vimeux M
Clin Hemorheol Microcirc; 1999; 21(3-4):329-34. PubMed ID: 10711765
[TBL] [Abstract][Full Text] [Related]
40. Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis.
Tejani A; Alexander S; Ettenger R; Lerner G; Zimmerman J; Kohaut E; Briscoe DM
Pediatr Transplant; 2004 Apr; 8(2):151-60. PubMed ID: 15049795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
